The Atlanta Equine Clinic The Atlanta Equine Clinic The Atlanta Equine Clinic

SCHEDULE APPOINTMENT ON-LINE CONSULTATION EVENTS & SEMINARS NEWSLETTER
QUESTIONS & ANSWERS CLIENT EDUCATION LIBRARY VETERINARY MEDICINE NEWS CASES OF INTERESTRELATED WEB LINKS
PHARMACY
HOME



 

ANNOUNCEMENTS CLASSIFIED ADS DISEASE UPDATE FARRIER'S CORNER PRODUCT UPDATE<BACK to NEWSLETTER

 

Fertilize Your Pastures

 

Bring Life to Your Land

call us at 678-867-2577

 

Implementing BioSecurity for Your Horse:

 

Equine Disease Communication Center

 


* MUST-HAVE Resources for Show Horse Owners
New Vaccination Rules for Show Horses (PDF)USEF Equine Influenza & EHV-1 Ruling (PDF)2016 Guidelines for Drugs & Medications (PDF) AAEP Infectious Disease Control GuidelinesBiosecurity Measures for Horse OwnersEquine Vaccination Record Form (PDF)

 

 EDCC

Equine Disease Communication Center Launches Outbreak Alert E-mail Service, Facebook and Twitter.

Owners, trainers, veterinarians and other equine industry participants can be alerted to infectious disease outbreaks and updates through an e-mail notification system recently implemented by the Equine Disease Communication Center (EDCC). The service is FREE. Alerts and other information are also posted on the EDCC’s social media platforms.

 

 

USEF

Everything you need to know about USEF’s new microchip rule
The USEF recently passed a rule requiring USHJA registered horses to be microchipped. As of 1 December 2017 all hunters, jumpers and equitation horses will need to have microchips in order to accumulate points.

 

 

Important Updates Regarding Medications:

 

PHENIBUT Considered a Prohibited Substance

A problematic substance has come to the attention of the USEF Equine Drugs and Medications Program. Phenibut (β-phenyl gamma aminobutyric acid) is considered a derivative of gamma aminobutyric acid (GABA), and effective immediately, phenibut, or any product containing phenibut (or β-phenyl gamma aminobutyric acid), is considered a forbidden substance under USEF rules. LEARN MORE

RMTC Board amends its list of controlled therapeutic medications

The RMTC’s scientific advisory committee to add four new medications to the current list of 26 Controlled Therapeutic Substances (CTS). The RMTC voted to add these four medications at the urging of the American Association of Equine Practitioners (AAEP).

Find out what those medications are HERE.

 

 

FDA Logo

FDA Alerts Horse Owners and Veterinarians About Adverse Events Associated with Certain Unapproved Compounded Drugs in Horses

Two lots of pyrimethamine/toltrazuril drugs compounded by Wickliffe Pharmacy have been associated with illnesses and deaths.
 
The U.S. Food and Drug Administration is alerting horse owners and veterinarians that two lots of compounded combination drug products containing pyrimethamine and toltrazuril, used to treat the neurologic disease Equine Protozoal Myeloencephalitis (EPM), have been associated with adverse events in ten horses.
 
The products were compounded by Wickliffe Pharmacy of Lexington, Ky. One lot was compounded as a paste and one as an oral suspension. All of the products in these lots are accounted for and are no longer in distribution.
 
FDA is working with the pharmacy and state partners to investigate these adverse events.
 
At this time, FDA testing indicates that one lot of product contained higher levels of pyrimethamine than the labeling indicates. Adverse events associated with high doses of pyrimethamine include seizures, fever and death.
 
FDA has received reports of adverse events--including seizures, fever and death--involving two horses in Kentucky and eight horses in Florida that were administered these products. Four horses have died or been euthanized and six horses are recovering.
 
Horse owners, caretakers and veterinarians should report to FDA any symptoms such as seizure, fever or collapse in horses who might have received high doses of pyrimethamine. During the course of this on-going investigation into the adverse reactions, it has come to the attention of FDA that elevated doses of pyrimethamine may have been used by some practitioners with negative results.   The usual dose of pyrimethamine in horses is 1 mg/kg, which has been shown to be safe for the treatment of EPM in an FDA-approved combination product containing pyrimethamine and sulfadiazine. These compounded combination products are not approved animal drugs. Additionally, toltrazuril is not approved for use in horses. In general, FDA has serious concerns about unapproved animal drugs, including certain compounded animal drugs. These drugs are not evaluated by FDA and may not meet FDA’s strict standards for safety and effectiveness. Unapproved animal drugs also may not be labeled or advertised appropriately. Horse owners or caretakers should consult with their veterinarians about other therapies.
 
Drugs that have been evaluated and approved by FDA for the treatment of EPM include ponazuril, diclazuril, and a combination drug of pyrimethamine and sulfadiazine. Owners and veterinarians can report complaints about FDA-regulated animal drug products by calling the consumer complaint coordinator in their area or by filing a Veterinary Adverse Drug Reaction report.

 

Information on reporting consumer complaints can be found HERE.
 
To report a Veterinary Adverse Drug Reaction to FDA (using a downloadable form) please click HERE.
 
Review the Journey of an Animal Drug through the Approval Process HERE.

 

 

If you have any questions regarding these Notices please call our office at (678) 867-2577. We look forward to serving you!
 
THE ATLANTA EQUINE CLINIC: 1665 Ward Road, Hoschton, Georgia 30548 - ph. 678-867-2577

home | schedule an appointment | on-line consultations | events & seminars | questions & answers | client library | veterinary news | case of the month | related web links | clinic pharmacy | AEC clothing | classified ads